Phibro Animal Health Corporation $PAHC Shares Acquired by Sei Investments Co.

Sei Investments Co. increased its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 15.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 156,948 shares of the company’s stock after purchasing an additional 21,339 shares during the period. Sei Investments Co. owned 0.39% of Phibro Animal Health worth $8,681,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. 1620 Investment Advisors Inc. increased its stake in Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after buying an additional 386 shares during the period. KBC Group NV purchased a new position in shares of Phibro Animal Health during the first quarter worth about $29,000. Rothschild Investment LLC grew its holdings in shares of Phibro Animal Health by 2,500.0% during the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after buying an additional 1,000 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new stake in Phibro Animal Health during the 3rd quarter valued at approximately $61,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $36.33 on Monday. Phibro Animal Health Corporation has a 52-week low of $25.58 and a 52-week high of $60.08. The company has a market capitalization of $1.47 billion, a PE ratio of 15.59, a price-to-earnings-growth ratio of 0.51 and a beta of 0.46. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The stock has a fifty day simple moving average of $32.71 and a 200-day simple moving average of $43.18.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The business had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities research analysts expect that Phibro Animal Health Corporation will post 3.08 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Wednesday, September 2nd. Phibro Animal Health’s dividend payout ratio is 20.60%.

Insider Activity

In related news, CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total transaction of $392,832.00. Following the sale, the chief executive officer owned 67,720 shares in the company, valued at approximately $3,778,776. This trade represents a 9.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 50.13% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on PAHC. Citigroup decreased their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Weiss Ratings lowered shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Phibro Animal Health has a consensus rating of “Hold” and a consensus target price of $42.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.